MY ACCOUNT | NEWSLETTER |

Chronic use of deslorelin in dogs


Deslorelin is currently registered for the induction of temporary infertility in male dogs, male cats, male ferrets and also prepubertal female dogs, but research has shown its usefulness for other conditions requiring chronic treatment. 

This paper presents six cases of dogs chronically treated with deslorelin for indications such as benign prostatic hyperplasia, control of fertility, abnormal reproductive behavior and urinary incontinence. 

All animals were in good health during treatment. Treatment duration was two to nine years. No short-term side effects were observed except for flare-up reactions, which were observed only in one in four intact males. 

Two dogs developed a neoplasia: a spayed bitch treated for urinary incontinence developed a pituitary carcinoma, and an intact male dog implanted for control of fertility developed a bladder carcinoma. While the pituitary carcinoma seems unlikely to be related to deslorelin, the bladder carcinoma could be due to the neutered condition of the dog (which was treated for nine years) as urinary tract neoplasia is more common in dogs following gonadectomy. 

Chronic treatment with deslorelin is regarded as safe when an animal is being treated for life. The possibility that a pause in the treatment might be helpful for the animal should be investigated.

Stefano Romagnoli, et al. “Chronic Use of Deslorelin in Dogs: Six Cases (2005-2022).” Animals (Basel). 2023 Jan 12;13(2):265. doi: 10.3390/ani13020265.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Cervical ventroflexion in cats 86 cases (2003-2024).

Like0
Dislike0

Prognostic Markers Associated with Short-Term Mortality in Dogs Hospitalised with Acute Pancreatitis A Retrospective Study of 192 Cases.

Like0
Dislike0

No light, no problem provision of light during simulated transport does not alter broiler chick performance or welfare outcomes.

Like0
Dislike0

Ohio State Launches Clinical Trial for Promising New Treatment for Acute Pancreatitis in Dogs

Like0
Dislike0

CMMB Launches Strategic Partnerships and Global Volunteer Initiatives to Strengthen Health Systems Worldwide

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top